- Home
- IMMP vs TSHA Comparison
IMMP vs TSHA Comparison
Compare IMMP & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- TSHA
- Stock Information
- Founded
- IMMP 1987
- TSHA 2019
- Country
- IMMP Australia
- TSHA United States
- Employees
- IMMP N/A
- TSHA N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- IMMP Health Care
- TSHA Health Care
- Exchange
- IMMP Nasdaq
- TSHA Nasdaq
- Market Cap
- IMMP 304.0M
- TSHA 334.1M
- IPO Year
- IMMP N/A
- TSHA 2020
- Fundamental
- Price
- IMMP $1.78
- TSHA $1.72
- Analyst Decision
- IMMP Buy
- TSHA Strong Buy
- Analyst Count
- IMMP 2
- TSHA 8
- Target Price
- IMMP $8.50
- TSHA $6.63
- AVG Volume (30 Days)
- IMMP 82.5K
- TSHA 1.6M
- Earning Date
- IMMP 03-25-2025
- TSHA 02-26-2025
- Dividend Yield
- IMMP N/A
- TSHA N/A
- EPS Growth
- IMMP N/A
- TSHA N/A
- EPS
- IMMP N/A
- TSHA N/A
- Revenue
- IMMP $3,019,249.00
- TSHA $8,333,000.00
- Revenue This Year
- IMMP N/A
- TSHA N/A
- Revenue Next Year
- IMMP $20.28
- TSHA N/A
- P/E Ratio
- IMMP N/A
- TSHA N/A
- Revenue Growth
- IMMP 24.11
- TSHA N/A
- 52 Week Low
- IMMP $1.65
- TSHA $1.19
- 52 Week High
- IMMP $3.34
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- IMMP 41.69
- TSHA 54.32
- Support Level
- IMMP $1.65
- TSHA $1.66
- Resistance Level
- IMMP $1.88
- TSHA $1.79
- Average True Range (ATR)
- IMMP 0.10
- TSHA 0.11
- MACD
- IMMP -0.01
- TSHA 0.01
- Stochastic Oscillator
- IMMP 41.94
- TSHA 47.62
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.